Compare Box Inc (BOX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Merck & Co., Inc. — how do they compare? Box Inc trades at $30.62 (market cap $4.16B), while Merck & Co., Inc. trades at $123.79 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 71.7× Box Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Box Inc pays none. Which is the better fit depends on your goals.
| BOX | MRK | |
|---|---|---|
Market Cap | $4.16B | $298.31B |
Sector | Technology | Health |
52-Week High | $33.55 | $129.52 |
52-Week Low | $21.37 | $77.60 |
Enterprise Value | $4.71B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $29.41, up 2.69% today, near its consensus price target low of $29.00. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.09B in 2025 with net income surging to $244.62M, reflecting a robust profit margin expansion. Recent earnings beats in Q4 2025 and Q1 2026 support positive sentiment, while the company expanded Box Zones globally to enhance data governance (Business Wire, 2026-06-30).
The outlook remains favorable with a $37.00 analyst price target implying 26% upside, backed by 60.7% buy ratings. Key risks include high P/E of 45.95 suggesting premium valuation, competitive pressures in content management, and debt levels requiring monitoring. Positive cash flow trends and strategic expansions provide growth catalysts, but investors should weigh valuation concerns against earnings momentum.
Merck (MRK) trades at $123.485, down 0.44% on the day, with a bullish technical signal and strong institutional accumulation. The company reported solid earnings beats in recent quarters despite a Q1 2026 loss, maintains robust profitability with a 73.91% gross margin and 13.59% net margin, and is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Cash flow from operations remains healthy at $16.47B for 2025, supporting strategic investments and shareholder returns.
Outlook remains positive with a $137.30 consensus price target representing 11% upside, supported by 67.57% analyst buy ratings. Key opportunities include pipeline expansion via M&A and sustained profitability, while risks involve integration of acquisitions, patent pressures, and competitive threats in oncology. The stock's valuation at 34.02 P/E appears elevated but justified by growth prospects and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
